2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-120049
    TAK-603 158146-85-1 98%
    TAK-603 is a potent and orally active antirheumatic agent. TAK-603 inhibits Thl-type cytokine production. TAK-603 has the potential for the research of adjuvant arthritis.
    TAK-603
  • HY-12005R
    Fingolimod hydrochloride (Standard) 162359-56-0 98%
    Fingolimod (hydrochloride) (Standard) is the analytical standard of Fingolimod (hydrochloride). This product is intended for research and analytical applications. Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator.
    Fingolimod hydrochloride (Standard)
  • HY-120090
    MRS1177 183721-13-3 98%
    MRS1177 is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist, with a Ki of 0.3 nM.
    MRS1177
  • HY-120107
    OAT-177 1799548-33-6 98%
    OAT-177 is a potent dual inhibitor targeting acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1) with an IC50=14.2 nM for human AMCase and IC50=232 nM for human CHIT1. OAT-177 is promising for research of chronic inflammatory and fibrotic-related lung diseases such as asthma and idiopathic pulmonary fibrosis.
    OAT-177
  • HY-120123
    FR181157 171046-15-4 98%
    FR181157, an orally active PGI2 agonist activity with especially good pharmacokinetic properties.
    FR181157
  • HY-120152
    SLP7111228 1449765-82-5 98%
    SLP7111228 is a SphK1 inhibitor. SLP7111228 reduces LPS-induced TNFα and IL-1β production. SLP7111228 can be used in neuroinflammatory diseases research.
    SLP7111228
  • HY-120167
    YM-44778 173941-74-7 98%
    YM-44778 is a neurokinin receptor antagonist. The pKi values for NK1, NK2 and NK3 are 8.08, 8.55 and 8.24, respectively. YM-44778 inhibits the increase of bladder pressure induced by substance [Sar9,Met(O2)11] -P (HY-P1012) in anestheticized rats.
    YM-44778
  • HY-120172
    WAY-126299A 169626-43-1 98%
    WAY-126299A is an orally active dual-acting 5-1ipoxygenase inhibitor (IC50: 12.2 μM) and leukotriene D4 antagonist (pKB: 6.4). WAY-126299A inhibits antigen-induced leukotriene-dependent bronchoconstriction. WAY-126299A can be used for research of asthma.
    WAY-126299A
  • HY-120214
    TAS05567 1429038-15-2 98%
    TAS05567 is a potent, highly selective, ATP-competitive and orally active Syk inhibitor with an IC50 of 0.37 nM. In a panel of 192 kinases, TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, JAK2, KDR and RET with IC50s of 10 nM, 4.8 nM, 600 nM and 29 nM, respectively). TAS05567 can be used for humoral immune-mediated inflammatory conditions such as autoimmune and allergic diseases.
    TAS05567
  • HY-120225
    NJK14047 1800576-41-3 98%
    NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice.
    NJK14047
  • HY-120245
    GSK-340 2222509-79-5 98%
    GSK-340 is a BET inhibitor with high affinity and significant selectivity for BD2 from BRD4 with a pIC50 of 7.2. GSK-340 inhibits MCP-1 release in Lipopolysaccharide (HY-D1056) treated PBMCs and whole blood with the pIC50 of 7.4 and 6.0, respectively. GSK-340 has immunomodulatory activity.
    GSK-340
  • HY-120246
    GS-5759 1346653-91-5 98%
    GS-5759 is both a β₂-adrenergic receptor agonist and a PDE4 inhibitor. GS-5759 increases intracellular cAMP levels by activating the β₂ receptor, promoting bronchial dilation. GS-5759 inhibits PDE4 activity, reduces cAMP degradation, and enhances anti-inflammatory effects. GS-5759 exhibits potent bronchial dilation and anti-inflammatory capabilities in animal models. GS-5759 can be used for research on respiratory diseases such as chronic obstructive pulmonary disease (COPD).
    GS-5759
  • HY-120268
    SLM6031434 1897379-33-7 98%
    SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD).
    SLM6031434
  • HY-120269
    CAY10512 139141-12-1
    CAY10512 is a NF-κB inhibitor. CAY10512 can suppress the upregulation of NF-κB-sensitive proinflammatory miRNAs (miRNA-9, miRNA-125b, miRNA-146a, miRNA-155) in cerebrospinal fluid and extracellular fluid. CAY10512 significantly reduces the release of pro-inflammatory cytokines (such as TNF-α, MCP-1, IL-8, IL-6). CAY10512 can be used for researchs on neuroinflammation, islet transplantation and microRNA regulation.
    CAY10512
  • HY-120273
    Glucocorticoids receptor agonist 3 305821-96-9 98%
    Glucocorticoids receptor agonist 3 is a potent agonist of glucocorticoids receptor. Glucocorticoids receptor agonist 3 is useful to research diseases, such as obesity, diabetes, and inflammation (extracted from patent WO2000066522A1, compound 345).
    Glucocorticoids receptor agonist 3
  • HY-120303
    LY269415 132392-65-5 98%
    LY269415, is an anti-oxidant agent, is a potent and orally active iron dependent lipid peroxidation and 5-lipoxygenase enzyme inhibitor. LY269415 has anti-inflammatory effects.
    LY269415
  • HY-12031B
    (2Z,3Z)-U0126 218601-62-8 98%
    (2Z,3Z)-U0126 is a selective inhibitor of MEK1 and MEK2, demonstrating potent antiinflammatory effects by noncompetitively inhibiting AP-1 transcriptional activity with IC50 values of 72 nM for MEK1 and 58 nM for MEK2. (2Z,3Z)-U0126 also inhibits anchorage-independent growth of Ki-ras-transformed rat fibroblasts by blocking both the extracellular signal-regulated kinase and mammalian target of rapamycin pathways. Additionally, (2Z,3Z)-U0126 can undergo isomerization and cyclization, resulting in various products that show reduced affinity for MEK and diminished AP-1 inhibition compared to the parent compound.
    (2Z,3Z)-U0126
  • HY-120381
    PD 136450 139067-52-0 98%
    PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats.
    PD 136450
  • HY-120451
    Salvinone 124681-15-8 98%
    Salvinone (Compound 49) is a compound that can be isolated from Salvia miltiorrhiza.
    Salvinone
  • HY-120457
    WYE-151650 1141855-86-8 98%
    WYE-151650 is a selective JAK-3 inhibitor. WYE-151650 suppresses IL-2-induced STAT-5 phosphorylation and cell proliferation mediated by JAK-3. WYE-151650 is promising for research of autoimmune diseases.
    WYE-151650
Cat. No. Product Name / Synonyms Application Reactivity